| 3546 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
es |
¿Qué es la fibromialgia? (Esenciales: hojas informativas de fácil lectura) |
La fibromialgia es un trastorno que causa dolores musculares y fatiga (cansancio). Las personas con fibromialgia tienen “puntos hipersensibles” en el cuerpo. Las personas que padecen de fibromialgia pueden también tener otros síntomas. |
| datos abiertos lista | 0.684212 |
| Mala memoria | 0.712723 |
| Centro Nacional | 0.614702 |
| principales sÃntomas | 0.701501 |
| NIAMS FOIA Aviso | 0.730336 |
| actividades relajantes | 0.635234 |
| Enter email address | 0.717473 |
|
| larga duración | 0.958254 |
| sueño reparador | 0.714685 |
| fuerte reacción | 0.713228 |
| siguientes acontecimientos | 0.706276 |
| siguientes medicamentos | 0.695912 |
| privacidad acceso | 0.606511 |
|
CLICK HERE |
| 3549 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
es |
La historia de Ana: Cómo ella y su familia aprendieron acerca de las lesiones deportivas. |
Ésta es una historia sobre una niña llamada Ana y cómo ella y su familia aprendieron acerca de las lesiones deportivas y cómo tratarlas. |
| exclama elena | 0.610573 |
| Centro Nacional | 0.597908 |
| abuelos juan | 0.561986 |
| CUIDARLOS ESTÉN | 0.551278 |
| NIAMS FOIA Aviso | 0.57986 |
| estrategia digital datos | 0.560384 |
| Don Juan | 0.554065 |
| doctor lópez | 0.624488 |
| niña llamada ana | 0.84278 |
| EVITAR LAS LESIONES | 0.575856 |
| Enter email address | 0.574045 |
| Ana pregunta | 0.796915 |
| esté lista | 0.669045 |
| tÃo tony | 0.587475 |
| ACTIVIDAD FÃ?SICA | 0.626752 |
| enfermedades musculoesqueléticas | 0.609448 |
| AMS Circle | 0.541394 |
| abuela isabel | 0.587691 |
| fractura aguda | 0.547676 |
|
| Doña Isabel | 0.58136 |
| Ana trota | 0.713138 |
| Elena carga | 0.607206 |
| Ana duda | 0.716124 |
| primos néstor | 0.624792 |
| BODY AND MIND | 0.573763 |
| las lesiones | 0.619815 |
| justo atrás | 0.568496 |
| médico indica ayuda | 0.583549 |
| comida esté lista | 0.605463 |
| pones hielo | 0.579881 |
| DE REHABILITACIÓN | 0.541692 |
| tÃa elena | 0.611387 |
| siguientes pasos | 0.553872 |
| gol ganador | 0.564997 |
| tÃo carlos | 0.967597 |
| MENUDO INCLUYEN EJERCICIOS | 0.604096 |
| DISTENSIÓN MUSCULAR | 0.543885 |
|
CLICK HERE |
| 3560 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
es |
¿Qué es la psoriasis? (Esenciales: hojas informativas de fácil lectura) |
La psoriasis es una enfermedad de la piel que causa descamación e inflamación (dolor, hinchazón, calentamiento y coloración). En la mayoría de los casos la psoriasis causa parches o placas de piel gruesa, enrojecida y con escamas plateadas. A cualquier persona le puede dar psoriasis, pero ocurre más frecuentemente en los adultos. |
| datos abiertos lista | 0.486446 |
| ​​por medicamentos | 0.493687 |
| Centro Nacional | 0.452752 |
| NIAMS FOIA Aviso | 0.513783 |
| Psoriasis guttata | 0.728018 |
| Enter email address | 0.503627 |
| causa lesiones | 0.828192 |
|
| Health Statistics | 0.460951 |
| Disease Control | 0.457636 |
| psoriasis causa lesiones | 0.753012 |
| pequeña muestra | 0.462355 |
| luz ultravioleta | 0.976683 |
| vÃas respiratorias | 0.479283 |
|
CLICK HERE |
| 15537 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Flu (Influenza) Vaccine Research |
NIAID flu vaccine research |
| risk assessment | 0.247548 |
| influenza infection | 0.280409 |
| 2014-2015 flu season | 0.47415 |
| flu vaccine production | 0.613927 |
| newly emerging influenza | 0.34218 |
| research efforts | 0.247925 |
| seasonal flu vaccines | 0.542694 |
| annual seasonal flu | 0.471143 |
| Disease Control | 0.250505 |
| new flu strain | 0.471191 |
| upcoming flu season | 0.477548 |
| antigenic drift | 0.307304 |
| research program | 0.246112 |
| yearly flu vaccine | 0.573896 |
| previous flu vaccinations | 0.495563 |
| time-consuming production process | 0.293358 |
| vaccine platforms | 0.325389 |
| vaccine effectiveness | 0.327853 |
| pandemic influenza research | 0.321638 |
| multiple flu strains | 0.573276 |
| human flu viruses | 0.500005 |
| influenza surveillance | 0.277497 |
| seasonal flu viruses | 0.515262 |
| Scientists | 0.218194 |
|
| influenza vaccine production | 0.39304 |
| universal flu vaccine | 0.691041 |
| multiple flu subtypes | 0.458878 |
| multiple flu seasons | 0.518895 |
| basic understanding | 0.248089 |
| Influenza pandemics | 0.282272 |
| U.S. Centers | 0.25193 |
| changes | 0.229679 |
| flu vaccine | 0.97962 |
| dominant strains | 0.296906 |
| globally circulating flu | 0.490336 |
| potential pandemic strains | 0.361387 |
| immune response | 0.256994 |
| person-to-person | 0.211008 |
| flu vaccine research | 0.531986 |
| seasonal flu vaccine | 0.95459 |
| protections | 0.210719 |
| vaccine strains | 0.377045 |
| NIAID | 0.29333 |
| unexpected flu strain | 0.481882 |
| people | 0.229954 |
| flu vaccine strain | 0.555725 |
| poor match | 0.24891 |
| key focus | 0.246436 |
|
CLICK HERE |
| 15540 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
NIAID Paylines -- NIAID Research Funding |
Fiscal year paylines for all award types. |
| Final NIAID Paylines | 0.905895 |
| POs contact information | 0.229921 |
| interim paylines | 0.666704 |
| success rates | 0.214968 |
| Email Alerts | 0.25735 |
| NIAID funds | 0.432012 |
|
| Research Project Success | 0.236611 |
| program officer | 0.217587 |
| overall impact/priority score | 0.255863 |
| initial paylines | 0.594349 |
| Research Portfolio Online | 0.237047 |
|
CLICK HERE |
| 15544 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Global Research in Cambodia |
NIAID-funded research in Cambodia focuses on HIV/AIDS, tuberculosis, malaria, and avian influenza. |
| reports | 0.235345 |
| avian influenza | 0.914596 |
| Cambodia | 0.841837 |
| Khmer population | 0.414517 |
| infectious diseases | 0.430183 |
| Cambodian center | 0.395105 |
| steady growth | 0.450129 |
| malaria-affected areas | 0.409225 |
| malaria research laboratory | 0.84082 |
| malaria drug resistance | 0.823015 |
| malaria treatment | 0.708295 |
| problem | 0.265615 |
| different settings | 0.392781 |
| micronutrients | 0.250825 |
| majority | 0.237584 |
| clinical study | 0.394312 |
| National Center | 0.391275 |
| NIAID-funded research | 0.424039 |
| Parasitology | 0.239748 |
| World Health Organization | 0.596215 |
| avian influenza infection | 0.641213 |
| Intramural Research | 0.416096 |
| clinical research studies | 0.584188 |
| NIAID DIR | 0.565328 |
|
| dengue fever | 0.447449 |
| malaria episode | 0.708655 |
| substandard antimalarial drugs | 0.668757 |
| future collaborative research | 0.563796 |
| natural protection | 0.406267 |
| multidrug resistance | 0.442439 |
| risk behavior | 0.399297 |
| CNM | 0.308846 |
| Phnom Penh | 0.425895 |
| Malaria Control | 0.663084 |
| healthcare | 0.237926 |
| research partnership | 0.40453 |
| counterfeit | 0.247239 |
| particular group | 0.407261 |
| HIV/AIDS | 0.343462 |
| Vector Research | 0.402611 |
| co-infection | 0.260805 |
| NIAID Division | 0.518719 |
| people | 0.265199 |
| malaria deaths | 0.695752 |
| Plasmodium falciparum parasite | 0.624047 |
| antiretroviral therapy | 0.419276 |
| treatment response | 0.400285 |
| education systems | 0.432324 |
|
CLICK HERE |
| 15548 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Tuberculosis TB, NIAID, NIH |
NIAID is examining TB at its fundamental levels through research to develop faster diagnosis, better vaccines, and shorter treatment times. |
| animal models | 0.484339 |
| treatment strategies | 0.479645 |
| new TB drug | 0.750789 |
| drug-resistant strains | 0.584127 |
| multidrug-resistant TB | 0.705257 |
| optimal drug combinations | 0.547291 |
| TB disease | 0.789313 |
| research findings | 0.480296 |
| severe airborne disease | 0.575915 |
| research | 0.505253 |
| new candidate drugs | 0.571748 |
| death worldwide | 0.485014 |
| novel TB drugs | 0.766874 |
| national history | 0.484991 |
| candidate drugs | 0.572469 |
| active TB disease | 0.746928 |
| TB deaths | 0.714042 |
| major causes | 0.487119 |
| MedlinePlus tuberculosis site | 0.583865 |
| genetic drug | 0.486206 |
| comprehensive portfolio | 0.485226 |
| TB bacterium | 0.688383 |
| latent infections | 0.478461 |
| middle-income countries | 0.49248 |
|
| risk factors | 0.478783 |
| World Health Organization | 0.559465 |
| research infrastructure | 0.479568 |
| early TB disease | 0.745692 |
| NIAID | 0.606471 |
| diagnostic potential | 0.480354 |
| people | 0.530993 |
| TB | 0.982786 |
| biomedical research | 0.486422 |
| new TB drugs | 0.754513 |
| HIV deaths | 0.484548 |
| Mycobacterium tuberculosis | 0.614224 |
| private industry | 0.478347 |
| public health practices | 0.540649 |
| TB diagnosis | 0.691172 |
| clinical studies | 0.55766 |
| prevention strategies | 0.478336 |
| NIAID priority | 0.54559 |
| vaccine clinical trials | 0.538763 |
| Mtb | 0.530457 |
| drug resistance | 0.554266 |
| causative agent | 0.484545 |
| basic research | 0.485797 |
|
CLICK HERE |
| 15552 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Dengue Fever, NIAID, NIH |
NIAID health and research information on dengue fever |
| dengue animal models | 0.637025 |
| related dengue viruses | 0.700576 |
| New research findings | 0.39085 |
| point-of-care machine | 0.349211 |
| dengue infection | 0.729539 |
| economic burden | 0.353666 |
| dengue vaccines | 0.665616 |
| muscle pain | 0.354058 |
| rapid dengue diagnosis | 0.618858 |
| small molecule drugs | 0.38263 |
| Western hemisphere | 0.353064 |
| clinical trials | 0.351867 |
| live-attenuated dengue viruses | 0.642326 |
| dengue-endemic countries | 0.348281 |
| dengue research projects | 0.662649 |
| diagnostic tests | 0.396946 |
| specific diagnostic tests | 0.387357 |
| human trials | 0.348533 |
| community-based prevention programs | 0.394083 |
| vaccine approach | 0.349325 |
| recombinant version | 0.351126 |
| viral factors | 0.354135 |
| dengue fever | 0.846342 |
| laboratory-based international surveillance | 0.396575 |
| rapid diagnostic tests | 0.391709 |
|
| healthcare providers | 0.353653 |
| treatment strategies | 0.350986 |
| United States | 0.35404 |
| global health threat | 0.393267 |
| dengue shock syndrome | 0.744003 |
| NIAID researchers | 0.395179 |
| infected people | 0.351147 |
| different viral dengue | 0.634725 |
| public health | 0.35259 |
| NIAID research priorities | 0.443797 |
| dengue disease | 0.600916 |
| recombinant proteins | 0.349944 |
| Health experts | 0.357315 |
| severe forms | 0.399676 |
| dengue | 0.999102 |
| viral proteins | 0.352028 |
| MedlinePlus dengue site | 0.654335 |
| viral vectors | 0.355429 |
| basic research activities | 0.394177 |
| dengue hemorrhagic fever | 0.763697 |
| NIAID projects | 0.394476 |
| new treatment options | 0.386411 |
| effective vaccine | 0.349229 |
| infectious disease | 0.367495 |
|
CLICK HERE |
| 15554 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Biodefense Category A, B, C Pathogens |
NIAID biodefense Category A, B, C pathogens |
| Additional Emerging Infectious | 0.832106 |
| Centers | 0.421008 |
| host defenses | 0.530437 |
| United States | 0.52892 |
| NIAIDÂ biodefense/EID mission | 0.732951 |
| highest priority | 0.718109 |
| Category C pathogens | 0.679223 |
| Biodefense Research | 0.623199 |
| U.S. Department | 0.53081 |
| complete scope | 0.522633 |
| Prevention | 0.420958 |
| conjunction | 0.425199 |
| Disease Control | 0.527974 |
| geographic range | 0.544192 |
| Emerging Infectious Diseases/Pathogens | 0.964432 |
| priority pathogens | 0.731074 |
| public health | 0.526578 |
| Notes | 0.420393 |
| pathogen threats | 0.55739 |
|
| national security | 0.524884 |
| HIV/AIDS | 0.422564 |
| Diseases/Pathogens category | 0.607089 |
| federal partners | 0.531115 |
| NIAID Emerging Infectious | 0.962085 |
| priority organisms/biological agents | 0.689595 |
| Category B pathogens | 0.686236 |
| Homeland Security | 0.535344 |
| intramural program management | 0.634748 |
| revision | 0.425668 |
| population | 0.422041 |
| NIAID Category | 0.742626 |
| biodefense effort | 0.588256 |
| highest risk | 0.556143 |
| pathogen priority list | 0.734849 |
| mass dissemination | 0.523841 |
| threat assessments | 0.532316 |
| Immunology studies | 0.522128 |
|
CLICK HERE |
| 15980 |
National Institute of Allergy and Infectious Diseases |
Video |
en |
Understanding Food Allergy |
The National Institute of Allergy and Infectious Diseases explains food allergy and offers tips on how to manage the condition. |
| TEDx Talks | 0.301209 |
| Food Allergy Enigma | 0.427335 |
| WARNING Signs | 0.307007 |
| Allergy Skin Tests | 0.422724 |
| ABS-CBN News | 0.319963 |
| Food Allergies | 0.800849 |
| Steve Paikin | 0.306473 |
| tips | 0.220462 |
| Untreated allergic reactions | 0.428934 |
| Mo10ta | 0.219842 |
| Anaphylaxis-Mayo Clinic | 0.294736 |
| Severe Food Allergies | 0.523532 |
| Sonia Hunt | 0.304266 |
| Duration | 0.977395 |
| Good Morning | 0.305532 |
| Dr. John Bergman | 0.374323 |
| eMedTV | 0.221562 |
| Stay Safe | 0.301006 |
| symptoms | 0.217567 |
| condition | 0.220423 |
| Infectious Diseases | 0.318448 |
| Foods | 0.218524 |
| Food Allergens | 0.31897 |
| Live Healthy | 0.301596 |
| Gluten Intolerance | 0.31617 |
|
| Mayo Clinic | 0.294446 |
| Cure Allergies FAST | 0.483591 |
| Signature Medical Group | 0.391029 |
| Food Intolerances | 0.341701 |
| boy | 0.235485 |
| Allergies Are Tired | 0.41865 |
| ABC News | 0.406616 |
| America | 0.2185 |
| Food Can Kill | 0.320007 |
| Severe Food Allergy | 0.452133 |
| views | 0.647848 |
| National Institute | 0.318188 |
| Immune Response | 0.297675 |
| Sensitivities | 0.221006 |
| Agenda | 0.21749 |
| NIAID | 0.224612 |
| food allergy | 0.513642 |
| Food Control Plan | 0.393618 |
| TEDxUCDavisSF | 0.217779 |
| Fatal Allergies | 0.417301 |
| National Geographic | 0.373164 |
| Rita Mustafa | 0.302426 |
| PsycheTruth | 0.219651 |
| Ana Pena | 0.303769 |
|
CLICK HERE |